BioPharma Credit Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	4.31	5.62	135.05	120.53	94.71	193.27
Cash & Short-Term Investments	4.31	5.62	135.05	120.53	94.71	193.27
Cash Growth	-88.41%	-95.84%	12.05%	27.26%	-51.00%	-34.85%
Accounts Receivable	54.21	31.71	20.23	19.73	9.59	0
Other Receivables	0.46	0.08	0.09	0.11	0.42	0.21
Receivables	54.67	31.8	20.32	19.84	10.01	0.21
Total Current Assets	58.98	37.42	155.37	140.37	104.72	193.48
Long-Term Investments	1,099	1,162	1,201	1,224	1,266	1,195
Total Assets	1,158	1,200	1,357	1,364	1,371	1,388
Accrued Expenses	7.49	16.94	15.87	24.35	6.34	9.39
Other Current Liabilities	-	0.95	-	1.95	-	-
Total Current Liabilities	7.49	17.88	15.87	26.3	6.34	9.39
Long-Term Unearned Revenue	-	0.06	-	0.26	0.56	-
Total Liabilities	7.49	17.94	15.87	26.56	6.9	9.39
Common Stock	13.74	13.74	13.74	13.74	13.74	13.74
Additional Paid-In Capital	607.13	607.13	607.13	607.13	607.13	607.13
Retained Earnings	529.45	560.81	720	716.59	742.85	758.05
Shareholders' Equity	1,150	1,182	1,341	1,337	1,364	1,379
Total Liabilities & Equity	1,158	1,200	1,357	1,364	1,371	1,388
Net Cash (Debt)	4.31	5.62	135.05	120.53	94.71	193.27
Net Cash Growth	-88.41%	-95.84%	12.05%	27.26%	-51.00%	-34.85%
Net Cash Per Share	0.00	0.00	0.10	0.09	0.07	0.14
Filing Date Shares Outstanding	1,129	1,140	1,254	1,319	1,374	1,374
Total Common Shares Outstanding	1,129	1,186	1,303	1,319	1,374	1,374
Working Capital	51.48	19.53	139.5	114.06	98.38	184.08
Book Value Per Share	1.02	1.00	1.03	1.01	0.99	1.00
Tangible Book Value	1,150	1,182	1,341	1,337	1,364	1,379
Tangible Book Value Per Share	1.02	1.00	1.03	1.01	0.99	1.00

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.